Vol. 2 No. 5 (2022): May
Health Technology Reviews

Cost-Effectiveness of Treatment for Pediatric Immune Thrombocytopenia

Published May 3, 2022

Key Messages

  • Limited evidence from 1 cost-consequence analysis study showed that eltrombopag was the preferred thrombopoietin receptor agonist over romiplostim (i.e., less expensive and more effective) for treatment of chronic immune thrombocytopenia in pediatric patients.
  • No cost-effectiveness studies of dapsone or rituximab were identified.